IBRX Stock Overview
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
ImmunityBio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.91 |
| 52 Week High | US$6.93 |
| 52 Week Low | US$1.25 |
| Beta | 0.039 |
| 1 Month Change | -9.58% |
| 3 Month Change | 36.39% |
| 1 Year Change | 114.41% |
| 3 Year Change | -72.89% |
| 5 Year Change | n/a |
| Change since IPO | -87.31% |
Recent News & Updates
Recent updates
ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise
Feb 27ImmunityBio: Buy Low Now Vs. Buy High Later
Feb 11ImmunityBio: PDUFA Pending
Oct 17ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain
Aug 07ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission
Jun 02ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter
Mar 15ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat
Dec 27ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price
Oct 12ImmunityBio: Market Has Lost Contact Following Merger
Jul 19ImmunityBio posts results from early-stage blood cancer study
May 04Shareholder Returns
| IBRX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.0% | -4.7% | -3.7% |
| 1Y | 114.4% | -2.7% | 20.2% |
Return vs Industry: IBRX exceeded the US Biotechs industry which returned -2% over the past year.
Return vs Market: IBRX exceeded the US Market which returned 20.5% over the past year.
Price Volatility
| IBRX volatility | |
|---|---|
| IBRX Average Weekly Movement | 17.1% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: IBRX's share price has been volatile over the past 3 months.
Volatility Over Time: IBRX's weekly volatility (17%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 628 | Rich Adcock | immunitybio.com |
ImmunityBio, Inc., a clinical-stage biotechnology company, engages in discovering, developing, and commercializing next-generation immuno- and cellular therapies for cancer and infectious diseases in the United States and Europe. The company offers immunotherapy and cell therapy platforms, including antibody cytokine fusion protein N-803, vaccine delivery technologies, and natural killer cell therapies. Its lead biologic commercial product candidate is Anktiva, an IL-15 superagonist antibody-cytokine fusion protein for the treatment of bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ with or without Ta or T1 disease.
ImmunityBio, Inc. Fundamentals Summary
| IBRX fundamental statistics | |
|---|---|
| Market cap | US$3.32b |
| Earnings (TTM) | -US$583.20m |
| Revenue (TTM) | US$622.00k |
5,344x
P/S Ratio-5.7x
P/E RatioIs IBRX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IBRX income statement (TTM) | |
|---|---|
| Revenue | US$622.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$622.00k |
| Other Expenses | US$583.82m |
| Earnings | -US$583.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 100.00% |
| Net Profit Margin | -93,761.41% |
| Debt/Equity Ratio | -143.1% |
How did IBRX perform over the long term?
See historical performance and comparison